Board meeting to approve results for quarter and half-year ended September 2026
PANACEABIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
No consolidated or standalone financial figures are provided in this notice. The Board is scheduled to meet on 14 November 2026 to approve the company's unaudited provisional results for the quarter and half-year ended 30 September 2026. The trading window for designated persons and their immediate relatives remains closed from 1 October 2026 to 16 November 2026.
This is only a meeting notice, with no confirmed earnings or cash-flow news yet. The approved results may affect investor sentiment and stock-price volatility.
The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.